Clinical implications of idiopathic pulmonary fibrosis and lung cancer
Idiopathic pulmonary fibrosis (IPF) is characterized by chronic progressive fibrosis of the lungs of unknown etiology. The prognosis of IPF is poor, with a median survival of 3 to 5 years. Lung cancer is one of the most frequently associated comorbidities of IPF, often resulting in grave outcomes. P...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sungkyunkwan University School of Medi
2025-03-01
|
| Series: | Precision and Future Medicine |
| Subjects: | |
| Online Access: | http://pfmjournal.org/upload/pdf/pfm-2025-00030.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850132127355502592 |
|---|---|
| author | Hongseok Yoo Man Pyo Chung |
| author_facet | Hongseok Yoo Man Pyo Chung |
| author_sort | Hongseok Yoo |
| collection | DOAJ |
| description | Idiopathic pulmonary fibrosis (IPF) is characterized by chronic progressive fibrosis of the lungs of unknown etiology. The prognosis of IPF is poor, with a median survival of 3 to 5 years. Lung cancer is one of the most frequently associated comorbidities of IPF, often resulting in grave outcomes. Patients with IPF have a higher risk for lung cancer than the general population. Lung cancer frequently develops in older male IPF patients with smoking history. Squamous cell carcinoma is the most common histological type, followed by adenocarcinoma. Such cancers typically develop abutting or within fibrosis. One of the major obstacles in making therapeutic decisions for these patients is the complications after treatment and subsequent poor prognosis. Numerous studies have reported post-treatment complications, such as acute exacerbation of IPF, pneumonia, and persistent air leakage, and their impact on survival. Higher mortality rates have consistently been reported among patients diagnosed with both IPF and lung cancer compared to those with either IPF or lung cancer alone. Thorough risk assessment for complications, selection of appropriate therapeutic modality, and use of antifibrotic agents, such as pirfenidone or nintedanib, may help prevent complications and improve survival. Nevertheless, further research is necessary to establish optimal treatment strategies for patients diagnosed with IPF and lung cancer. |
| format | Article |
| id | doaj-art-cbe51ddfe398421bb40cc5de814bf70f |
| institution | OA Journals |
| issn | 2508-7940 2508-7959 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Sungkyunkwan University School of Medi |
| record_format | Article |
| series | Precision and Future Medicine |
| spelling | doaj-art-cbe51ddfe398421bb40cc5de814bf70f2025-08-20T02:32:18ZengSungkyunkwan University School of MediPrecision and Future Medicine2508-79402508-79592025-03-0191354210.23838/pfm.2025.00030183Clinical implications of idiopathic pulmonary fibrosis and lung cancerHongseok Yoo0Man Pyo Chung1 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaIdiopathic pulmonary fibrosis (IPF) is characterized by chronic progressive fibrosis of the lungs of unknown etiology. The prognosis of IPF is poor, with a median survival of 3 to 5 years. Lung cancer is one of the most frequently associated comorbidities of IPF, often resulting in grave outcomes. Patients with IPF have a higher risk for lung cancer than the general population. Lung cancer frequently develops in older male IPF patients with smoking history. Squamous cell carcinoma is the most common histological type, followed by adenocarcinoma. Such cancers typically develop abutting or within fibrosis. One of the major obstacles in making therapeutic decisions for these patients is the complications after treatment and subsequent poor prognosis. Numerous studies have reported post-treatment complications, such as acute exacerbation of IPF, pneumonia, and persistent air leakage, and their impact on survival. Higher mortality rates have consistently been reported among patients diagnosed with both IPF and lung cancer compared to those with either IPF or lung cancer alone. Thorough risk assessment for complications, selection of appropriate therapeutic modality, and use of antifibrotic agents, such as pirfenidone or nintedanib, may help prevent complications and improve survival. Nevertheless, further research is necessary to establish optimal treatment strategies for patients diagnosed with IPF and lung cancer.http://pfmjournal.org/upload/pdf/pfm-2025-00030.pdfcomplicationsidiopathic pulmonary fibrosislung neoplasmstherapeutics |
| spellingShingle | Hongseok Yoo Man Pyo Chung Clinical implications of idiopathic pulmonary fibrosis and lung cancer Precision and Future Medicine complications idiopathic pulmonary fibrosis lung neoplasms therapeutics |
| title | Clinical implications of idiopathic pulmonary fibrosis and lung cancer |
| title_full | Clinical implications of idiopathic pulmonary fibrosis and lung cancer |
| title_fullStr | Clinical implications of idiopathic pulmonary fibrosis and lung cancer |
| title_full_unstemmed | Clinical implications of idiopathic pulmonary fibrosis and lung cancer |
| title_short | Clinical implications of idiopathic pulmonary fibrosis and lung cancer |
| title_sort | clinical implications of idiopathic pulmonary fibrosis and lung cancer |
| topic | complications idiopathic pulmonary fibrosis lung neoplasms therapeutics |
| url | http://pfmjournal.org/upload/pdf/pfm-2025-00030.pdf |
| work_keys_str_mv | AT hongseokyoo clinicalimplicationsofidiopathicpulmonaryfibrosisandlungcancer AT manpyochung clinicalimplicationsofidiopathicpulmonaryfibrosisandlungcancer |